Overall rank by patents
#24,305
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 11 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G06V (IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING).
The verdict
Evolv holds 11 US patents across 11 technology areas, rank #24,305 of 50,000 tracked assignees.
Evolv Technologies, Inc. has been granted 11 US utility patents between 2017 and 2025, placing Evolv Technologies, Inc. at rank #24,305 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.8 claims per patent with primary concentration in G06V (IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING). As a US Corporation, Evolv Technologies, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Evolv sits between Estetra SPRL (11 patents, rank #24,301) and F-star Therapeutics Limited (11 patents, rank #24,309) - the closest US assignees by grant volume. The composite Innovation Score of 40.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 4 in the 2015–2019 window, a +75% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Evolv Technologies, Inc.'s 24.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Evolv Technologies, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Estetra SPRL
11 patents
Eutropics Pharmaceuticals, Inc.
11 patents
EverPro Technologies Company Limited
11 patents
Everbridge, Inc.
11 patents
Exinda Networks PTY, Ltd.
11 patents
ExlService Holdings, Inc.
11 patents
Ezaki Glico Co. Ltd.
11 patents
F-star Therapeutics Limited
11 patents
Evolv Technologies, Inc.
11 patents
What this shows Evolv holds 11 patents at rank #24,305, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Evolv's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
40 Top 36% higher than 64% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 2 | 18.2% |
| 2019 | 2 | 18.2% |
| 2020 | 2 | 18.2% |
| 2022 | 1 | 9.1% |
| 2023 | 1 | 9.1% |
| 2024 | 1 | 9.1% |
| 2025 | 2 | 18.2% |
Top 11 of 11 technology areas
Overall rank by patents
#24,305
Across all tracked assignees
40.2 out of 100
How to use this portfolio
Evolv's 11 grants land it in the top 36% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.